ANB033

About AnaptysBio

AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.

About AnaptysBio

AnaptysBio is a clinical-stage biotech advancing a pipeline of best-in-class antibodies designed to dampen inflammatory responses and restore immune balance in autoimmune and inflammatory diseases. The company has demonstrated its antibody discovery capabilities through out-licensed assets like Jemperli (GSK) and imsidolimab (Vanda Pharmaceuticals), which provide royalty revenue. Strategically, AnaptysBio has announced its intent to separate its biopharma operations from its royalty assets by year-end 2026, aiming to create two distinct investment vehicles focused on development and financial assets, respectively.

Therapeutic Areas